Author(s)

Rie Miyazaki¹, Hiroyuki Yasui¹, Yutaka Yoshikawa^1,2*

¹Department of Analytical and Bioinorganic Chemistry, Kyoto Pharmaceutical University, Kyoto, Japan.
²Department of Health, Sports, and Nutrition, Faculty of Health and Welfare, Kobe Women’s University, Hyogo, Japan.

There are many reports that divalent alkaline earth, first-row transition metals, and Zn(II) ions have α-glucosidase inhibitory effects. Cu(II) and Zn(II) ions, in particular, have strong α-glucosidase inhibitory effects. Several Schiff bases also display α-glucosidase inhibitory effects. In this study, we focused on safe and highly effective complexes including Zn(II) ion. We prepared and characterized the Zn(II) complexes with four different Schiff bases (N-salicylidene-β-alanine (N-sβ), N-N’-bis (salicylidene) ethylenediamine (N-bsE), N, N’-bis (salicylidene)-phenylenediamine (N-bsP), and 1-[(2-dimethylaminoethylimino) methyl]naphtholate (DMN)) and investigated their α-glucosidase inhibitory effects in vitro, using α-glycosidases from Saccharomyces sp. and rat small intestine, and in vivo, using a sucrose tolerance test. The Zn(II) complexes with DMN showed the highest in vitro and in vivo α-glucosidase inhibitory effects in this study.

α-Glucosidase Inhibitory Effect, Zn(II) Complexes, Schiff Bases, Diabetes Mellitus

Miyazaki, R. , Yasui, H. and Yoshikawa, Y. (2016) α-Glucosidase Inhibition by New Schiff Base Complexes of Zn(II). Open Journal of Inorganic Chemistry, 6, 114-124. doi: 10.4236/ojic.2016.62007.